Side-by-side comparison of AI visibility scores, market position, and capabilities
Dallas largest US natural gas-only utility (NYSE: ATO) ~$4.3B FY2024 revenue; 3.3M customers in 8 states, Texas population boom tailwind, 6-8% annual EPS growth, $3.5B/year capex competing with CenterPoint.
Atmos Energy Corporation is a Dallas, Texas-based natural gas distribution company — publicly traded on the New York Stock Exchange (NYSE: ATO) as an S&P 500 Utilities component — distributing natural gas to approximately 3.3 million residential, commercial, and industrial customers in eight states (Texas, Louisiana, Mississippi, Tennessee, Kentucky, Kansas, Colorado, and Virginia) through approximately 4,500 employees, operating as the largest natural gas-only utility in the United States by customer count. In fiscal year 2024 (ending September 2024), Atmos Energy reported revenues of approximately $4.3 billion and adjusted earnings per diluted share of $7.03 — continuing Atmos Energy's consistent 6-8% annual EPS growth track record that has made Atmos Energy one of the most reliable earnings growth utilities in the US, supported by the multi-state regulatory framework that allows Atmos to recover capital investment through formula rate mechanisms in most of its eight service states. CEO Chris Forsythe leads Atmos Energy's capital investment program — $3.5 billion annually in pipeline system modernization (replacing vintage cast iron, bare steel, and mechanically coupled pipe with modern coated steel and plastic distribution pipe), safety system upgrades, and capacity expansion in high-growth Texas and Colorado markets. Texas remains Atmos Energy's dominant service territory (2+ million of 3.3 million customers, serving Dallas-Fort Worth metro, Houston, San Antonio, El Paso, and West Texas) where residential and commercial natural gas demand growth from the Texas population boom (DFW growing 150,000 residents annually) drives Atmos Energy's capital investment and revenue growth.
Global pharma company with $55B 2024 revenue; successfully diversifying beyond Humira with Skyrizi, Rinvoq, and $8.7B Cerevel neuroscience acquisition.
AbbVie is a global research-based biopharmaceutical company focused on developing treatments for complex and serious diseases including immunology, oncology, neuroscience, aesthetics, and eye care. Spun off from Abbott Laboratories in 2013 and headquartered in North Chicago, Illinois, AbbVie rapidly became one of the world's top pharmaceutical companies on the strength of Humira — the world's best-selling drug for over a decade with peak annual sales exceeding $20 billion. AbbVie is listed on the NYSE and is a component of the S&P 500 and Dow Jones Industrial Average.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.